Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Abstract Background Immune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless, only a subset of patients benefit, even when selected based on approved biomarkers such as PD-L1 and tumor mutational burden. New biomarkers a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Harsha Ranganath, Amit L. Jain, Justin R. Smith, Julie Ryder, Amina Chaudry, Emily Miller, Felicia Hare, Poojitha Valasareddy, Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, Tyler J. Nielsen, Janice Mullins, Douglas T. Ross, David R. Gandara, Gregory A. Vidal
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2022-04-01
Colecção:BMC Cancer
Assuntos:
Tumor biomarkers
Immunotherapy
Gene expression profiling
Programmed death ligand 1
Tumor microenvironment
Acesso em linha:https://doi.org/10.1186/s12885-022-09470-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados